July 03, 2026

Dr. Felix Kommoss awarded the 2026 Rudolf Virchow Prize

Dr. Felix Kommoss awarded the 2026 Rudolf Virchow Prize

For his research on the development of rare malignant tumors in the hereditary DICER1 tumor predisposition syndrome, Dr. Felix Kommoss has been awarded the Rudolf Virchow Prize of the German Society of Pathology (Deutsche Gesellschaft für Pathologie, DGP) – the most prestigious research award in the field of pathology in Germany. Dr. Kommoss conducts research at the Heidelberg Faculty of Medicine at Heidelberg University and serves as Senior Physician and Head of Gynecologic Pathology at the Institute of Pathology, Heidelberg University Hospital.

DGP Board Member Prof. Dr. Claudia Wickenhauser and Dr. Felix Kommoss at the Rudolf Virchow Prize award ceremony in Augsburg in late May. Photo: DGP

DICER1 tumor predisposition syndrome is a rare hereditary condition that increases the risk of developing a range of tumors. It is caused by alterations in the DICER1 gene, which plays a key role in normal cell growth and cell division in the human body. Affected individuals often develop tumors in childhood or early adulthood, some of which follow an aggressive clinical course. Working with an international research team, Dr. Felix Kommoss identified a population of connective tissue precursor cells as a potential origin of DICER1-associated tumors and traced how different tumor cell types emerge from these cells. “Our findings contribute to a better understanding of the development of these previously understudied tumors and may, in the long term, provide a foundation for new diagnostic and therapeutic approaches,” says Dr. Felix Kommoss.

In the award-winning study, the researchers used a mouse model to determine which cells give rise to these tumors, where these cells are located within the tissue, and how they change over the course of tumor development. The results, published in the journal Nature Communications, show that distinct tumor cell types arise from specific connective tissue precursor cells, including muscle-like cells as well as particularly rapidly proliferating tumor cells that are associated with a more aggressive disease. Comparable cell populations and developmental trajectories were also identified in human tumor samples.

The study, supported by the German Research Foundation (DFG), builds on work conducted by Dr. Felix Kommoss during his postdoctoral research in the laboratory of Professor David Huntsman at the University of British Columbia, Canada, and at BC Cancer, a Canadian organization for cancer care and research based in Vancouver. The Rudolf Virchow Prize, endowed with €5,000, is awarded annually by the German Society of Pathology (DGP) to researchers under the age of 40 for a scientific publication that has recently been published or not yet published at the time of submission.

Original publication

Kommoss FKF, Zhang JYH, Lynch BJ et al. Spatial single cell transcriptomic analysis informs tumor developmental hierarchy of DICER1 syndrome related sarcoma. Nat Commun 17, 4608 (2026). https://doi.org/10.1038/s41467-026-70971-6

Further information is available online

Review of the award ceremony on the DGP website (in German) 

Information about the Rudolf Virchow Prize (in German) 

Website of the Institute of Pathology at UKHD (in German)

Contact

Dr. Felix Kommoss
Heidelberg Faculty of Medicine at Heidelberg University
Head of Gynecologic Pathology 
Institute of Pathology, Heidelberg University Hospital
+49 6221 56-32516
felix.kommoss@med.uni-heidelberg.de

Our latest News

discover more
2026 BioTech Breakthrough Honors VectorBuilder With “Overall CGT Solution Provider of the Year”

2026 BioTech Breakthrough Honors VectorBuilder With “Overall CGT Solution Provider of the Year”

Annual awards program recognizes innovation in life sciences and biotechnology worldwide CHICAGO, November 5, 2026 – VectorBuilder, a global leader in gene delivery technologies, today announced it has been named “Overall CGT Solution Provider of the Year” in the sixth annual BioTech Breakthrough Awards, recognizing innovation across the global life sciences and biotechnology industries. VectorBuilder integrates vector […]

Breast Milk for the Youngest Babies: New Milk Bank at Heidelberg University Hospital

Breast Milk for the Youngest Babies: New Milk Bank at Heidelberg University Hospital

The Heidelberg University Hospital (UKHD) recently launched “HeidelMilk,” a breast milk donation bank. It provides premature infants with donated breast milk when their own mothers’ milk supply is insufficient. To mark World Prematurity Day on November 15, the UKHD is introducing this new service. Full Text in German below. Muttermilch für die Kleinsten: Neue Milchbank […]

When Brake Cells Become Killer Cells: Double Honor for DKFZ Researcher Julius Michel

When Brake Cells Become Killer Cells: Double Honor for DKFZ Researcher Julius Michel

Julius Michel, a postdoctoral researcher at the German Cancer Research Center (DKFZ), has received two awards: the Craig Tendler Award for Myeloma Research from the American Society of Hematology – awarded for the first time and accompanied by a $10,000 prize – as well as another award from the society. He has discovered that a […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp